Contributions
Abstract: P1300
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Introduction: Multiple Sclerosis (MS) is the principal cause of non-traumatic disability among young adults. Fampridine prolongs action potentials through the blockage of potassium channels, thus ameliorating neurotransmission in demyelinated axons and improving motor disability in patients with MS. Several post-marketing studies suggest fampridine might be beneficial in other domains.
Objectives: The aim of this study was to assess the effects of treatment with fampridine on life quality, fatigue and mood among MS patients.
Methods: Prospective, post-marketing, single-center study, recruiting consecutive Portuguese patients eligible for treatment with fampridine, from November 2015 to March 2016. Evaluations were performed at baseline (D0) and after 14 days (D14) of treatment for gait velocity by Timed 25-Foot Walk (T25FW), quality of life through Functional Assessment of Multiple Sclerosis (FAMS), fatigue through Fatigue Severity Scale (FSS) and mood using the Hospital Anxiety and Depression Scale (HADS). Responders were defined as those having improved 20% or more in the T25FW at D14.
Results: Twenty patients were included with different types of MS, 65% females, with a median age of 53 years old and a median Expanded Disability Status Scale of 6.0. Twelve patients (60%) were responder by D14 and in this group a significant improvement was observed comparing with D0 in FSS (median 39,0 vs 46,0; p=0,032) and FAMS (median 125 vs 115; p=0,012). In non-responders there was no significant improvement of FSS (median 37,5 vs 40,5; p=1,000) or FAMS (median 84,5 vs 82,5; p=0,932) after 14 days of therapy. Responders and non-responders did not present significant differences in mood score (HADS).
Conclusions: Our results suggest a potential role of fampridine in improving not only walking speed but also other MS symptoms, namely life quality and fatigue, especially among timed walk responders. Further randomized, placebo-controlled studies will be needed to establish a definite role of fampridine in these domains.
Disclosure: Ariana Barros: nothing to disclose
João Sequeira: nothing to disclose
Soraia Vaz: nothing to disclose
Joana Morgado: nothing to disclose
Pedro Brás: nothing to disclose
Diana Melancia: nothing to disclose
Andreia Fernandes: nothing to disclose
Ary Sousa: nothing to disclose
Sara Dias: nothing to disclose
Carlos Capela: nothing to disclose
Rui Pedrosa: nothing to disclose
Abstract: P1300
Type: Poster
Abstract Category: Therapy - symptomatic - Treatment of specific symptoms
Introduction: Multiple Sclerosis (MS) is the principal cause of non-traumatic disability among young adults. Fampridine prolongs action potentials through the blockage of potassium channels, thus ameliorating neurotransmission in demyelinated axons and improving motor disability in patients with MS. Several post-marketing studies suggest fampridine might be beneficial in other domains.
Objectives: The aim of this study was to assess the effects of treatment with fampridine on life quality, fatigue and mood among MS patients.
Methods: Prospective, post-marketing, single-center study, recruiting consecutive Portuguese patients eligible for treatment with fampridine, from November 2015 to March 2016. Evaluations were performed at baseline (D0) and after 14 days (D14) of treatment for gait velocity by Timed 25-Foot Walk (T25FW), quality of life through Functional Assessment of Multiple Sclerosis (FAMS), fatigue through Fatigue Severity Scale (FSS) and mood using the Hospital Anxiety and Depression Scale (HADS). Responders were defined as those having improved 20% or more in the T25FW at D14.
Results: Twenty patients were included with different types of MS, 65% females, with a median age of 53 years old and a median Expanded Disability Status Scale of 6.0. Twelve patients (60%) were responder by D14 and in this group a significant improvement was observed comparing with D0 in FSS (median 39,0 vs 46,0; p=0,032) and FAMS (median 125 vs 115; p=0,012). In non-responders there was no significant improvement of FSS (median 37,5 vs 40,5; p=1,000) or FAMS (median 84,5 vs 82,5; p=0,932) after 14 days of therapy. Responders and non-responders did not present significant differences in mood score (HADS).
Conclusions: Our results suggest a potential role of fampridine in improving not only walking speed but also other MS symptoms, namely life quality and fatigue, especially among timed walk responders. Further randomized, placebo-controlled studies will be needed to establish a definite role of fampridine in these domains.
Disclosure: Ariana Barros: nothing to disclose
João Sequeira: nothing to disclose
Soraia Vaz: nothing to disclose
Joana Morgado: nothing to disclose
Pedro Brás: nothing to disclose
Diana Melancia: nothing to disclose
Andreia Fernandes: nothing to disclose
Ary Sousa: nothing to disclose
Sara Dias: nothing to disclose
Carlos Capela: nothing to disclose
Rui Pedrosa: nothing to disclose